Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Weight change and long-term cardiovascular outcomes in overweight and obese patients after acute coronary syndromes.

European heart journal open·2026
Same author

Safety of low lipoprotein(a) levels: the FOURIER trial.

European heart journal·2026
Same author

Revue medicale suisse·2026
Same author

[Chronic coronary syndrome : advanced cardiac imaging].

Revue medicale suisse·2026
Same author

[Chagas cardiomyopathy].

Revue medicale suisse·2026
Same author

Erratum to "2025 Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias" [Atherosclerosis, 409, (October 2025), 120479].

Atherosclerosis·2026

Video Experimental Relacionado

Updated: Jun 23, 2026

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

Las estatinas como agentes inmunomoduladores.

François Mach1

  • 1Cardiology Division, Department of Medicine, University Hospital, Geneva Medical School, Foundation for Medical Research, Geneva, Switzerland. francois.mach@medicine.unige.ch

Circulation
|June 3, 2004
PubMed
Resumen
Este resumen es generado por máquina.

Las estatinas pueden suprimir las respuestas inmunes al inhibir la inducción de las moléculas del complejo de histocompatibilidad mayor clase II (MHC-II). Este hallazgo sugiere que las estatinas podrían usarse como agentes inmunosupresores en el trasplante de órganos.

Más Videos Relacionados

Purification of Human S100A12 and Its Ion-induced Oligomers for Immune Cell Stimulation
12:55

Purification of Human S100A12 and Its Ion-induced Oligomers for Immune Cell Stimulation

Published on: September 29, 2019

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

Videos de Experimentos Relacionados

Last Updated: Jun 23, 2026

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

Purification of Human S100A12 and Its Ion-induced Oligomers for Immune Cell Stimulation
12:55

Purification of Human S100A12 and Its Ion-induced Oligomers for Immune Cell Stimulation

Published on: September 29, 2019

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

Área de la Ciencia:

  • Inmunología Inmunología.
  • Farmacología Farmacología.
  • Biología celular Biología celular.

Sus antecedentes:

  • Las estatinas son principalmente conocidas por reducir la síntesis de colesterol.
  • El mevalonato, un precursor en la síntesis del colesterol, también es vital para la producción de isoprenoides, que regulan las funciones celulares.
  • Las moléculas del complejo mayor de histocompatibilidad clase II (MHC-II) son cruciales para las respuestas inmunes y el rechazo del trasplante de órganos, y su expresión puede ser inducida por el interferón gamma (IFN-gamma).

Objetivo del estudio:

  • Investigar los posibles efectos pleiotrópicos de las estatinas más allá de la reducción del colesterol.
  • Para determinar si las estatinas influyen en la regulación de la expresión de MHC-II inducida por IFN-gamma en células humanas.

Principales métodos:

  • Las células endotelial humanas cultivadas y los monocitos/macrófagos fueron tratados con estatinas.
  • Se analizó el efecto de las estatinas en la expresión de MHC-II inducida por IFN-gamma.

Principales resultados:

  • Se observó que las estatinas reprimen la inducción de la expresión de MHC-II por IFN-gamma.
  • Esta represión se produjo tanto en las células endoteliales como en los monocitos/macrófagos.

Conclusiones:

  • Las estatinas exhiben propiedades inmunosupresoras al inhibir la inducción del MHC-II.
  • Estos hallazgos proporcionan una explicación molecular de los efectos inmunosupresores observados de las estatinas en ensayos clínicos de trasplante de órganos.
  • Las estatinas pueden representar una nueva opción terapéutica como agentes inmunosupresores en entornos de trasplante.